Bionoid Pharma, Inc.
BINP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.00 | -456.65 | 6.86 |
| FCF Yield | 0.00% | 0.00% | -0.03% | -0.02% |
| EV / EBITDA | 0.00 | -4,554.31 | 13,918.87 | -702.39 |
| Quality | ||||
| ROIC | 0.00% | 31.74% | 2.36% | -103.38% |
| Gross Margin | 0.00% | 22.44% | 48.13% | 45.05% |
| Cash Conversion Ratio | -0.03 | -13.97 | 0.22 | 0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -28.39% | 5.54% | 22.05% |
| Free Cash Flow Growth | 0.00% | 101.11% | -7.21% | 58.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -35.20 | 31.36 | -1.00 |
| Interest Coverage | -167.82 | 7.61 | 4.89 | -203.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3.14 | -87.81 | 103.04 |